|
Razi Cov Pars
Razi Cov Pars ( fa, رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute. It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine. It received emergency use authorization in Iran on 31 October 2021. Medical uses It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray). Pharmacology Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein. Manufacturing It's planned to produce one million doses of the vaccine each month as of September 2021. As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health. History Clinical trials Authorizations Raz Cov Pars received emergency use authorization in Iran on 31 October 2021. See also * Pharmaceuticals in Iran * COVID-19 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Severe Acute Respiratory Syndrome Coronavirus 2
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a strain of coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus previously had a Novel coronavirus, provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called the human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a public health emergency of international concern on January 30, 2020, and a pandemic on March 11, 2020. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is Contagious disease, contagious in humans. SARS‑CoV‑2 is a virus of the species ''severe acute respiratory syndrome–related coronavirus'' (SARSr-CoV), related to the Severe acute respiratory syndrome coronavirus 1, SARS-CoV-1 virus that caused the 2002–2004 SARS outbreak. Despite its close relation to SARS-CoV-1, i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Subunit Vaccine
A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. A "subunit" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides. Because the vaccine doesn't contain "live" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccine containing whole pathogens. Other advantages include being well-established technology and being suitable for immunocompromised individuals. Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine which antigenic combinations may work best. Mechanism Subunit vaccines contain fragments of the pathogen, such as protein or polysaccharide, whose combinations are carefully selected to i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Science And Technology In Iran
Iran has made considerable advances in science and technology through education and training, despite international sanctions in almost all aspects of research during the past 30 years. Iran's university population swelled from 100,000 in 1979 to 2 million in 2006. In recent years, the growth in Iran's scientific output is reported to be the fastest in the world. Science in ancient and Medieval Iran (Persia) Beginning in ancient times Persia has been a center of scientific achievement and was often the conduit of knowledge from China and India in the East to Greece and Rome in the West. Persian-speaking scholars have been active in furthering knowledge in fields of science and technology, such as astronomy, chemistry, anatomy, biology, botany, cosmology, mathematics, engineering, and architecture. Science in Persia evolved in two main phases separated by the arrival and widespread adoption of Islam in the region. References to scientific subjects such as natural science and ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Clinical Trials
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted. Depending on product type and development stage, investigators initially enroll volunteers or patients into small pilot studies, and subsequently conduct progressively larger scale comparative studies. Clinical trials can vary i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
COVID-19 Vaccine Clinical Research
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 COVID-19 vaccine, vaccines. These characteristics include #Efficacy, efficacy, #Effectiveness, effectiveness and safety. , 40 vaccines are authorized by at least one national regulation of therapeutic goods, regulatory authority for public use: * one DNA vaccine: ZyCoV-D * four RNA vaccines: Pfizer–BioNTech COVID-19 vaccine, Pfizer–BioNTech, Moderna COVID-19 vaccine, Moderna, Walvax COVID-19 vaccine, Walvax, and HGC019, Gemcovac * twelve inactivated vaccines: Chinese Academy of Medical Sciences COVID-19 vaccine, Chinese Academy of Medical Sciences, CoronaVac, Covaxin, CoviVac (Russia COVID-19 vaccine), CoviVac, COVIran Barekat, FAKHRAVAC, Minhai COVID-19 vaccine, Minhai-Kangtai, QazCovid-in, QazVac, Sinopharm Sinopharm BIBP COVID-19 vaccine, BIBP, Sinopharm WIBP COVID-19 vaccine, WIBP, Turkovac, and Valneva COVID-19 vaccine, VLA2001. * six viral vector vaccines: Sputnik Li ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
COVID-19 Pandemic In Iran
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 are variable but often include fever, cough, headache, fatigue, breathing difficulties, loss of smell, and loss of taste. Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms. Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are at a higher risk of developing severe ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pharmaceuticals In Iran
''For health issues in Iran see Health in Iran.'' Healthcare in Iran is based on three pillars: the public-governmental system, the private sector, and NGOs. The healthcare and medical sector's market value in Iran was almost US$24 billion in 2002 and is forecast to rise to US$96 billion in 2017. With a population of 80 million (2017), Iran is one of the most populous countries in West Asia. The country faces the common problem of other young demographic nations in the region, which is keeping pace with growth of an already huge demand for various public services. The young population will soon be old enough to start new families, which will boost the population growth rate and subsequently the need for public health infrastructures and services. Total healthcare spending is expected to rise from $24.3 billion in 2008, to $96 billion by 2017, reflecting the increasing demand on medical services. Total health spending was equivalent to 6% of GDP in Iran in 2017. About 90% of Irania ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ministry Of Health And Medical Education
The Ministry of Health and Medical Education (MOHME) has executive responsibility for health and medical education within the Iranian government. The MOHME comprises five departments headed by deputy ministers: # Research and Technology #Education #Logistics #Food and Drugs #Health Iran's health system is highly centralized, and almost all decisions regarding general goals, policies and allocation of resources are made at the central level by MOHME. The Ministry has the legal authority to oversee, license and regulate the activities of the private health sector.The role of contractual arrangements in improving health sector performance page 5 An elaborate system of health network provides |
Coronavirus Spike Protein
Spike (S) glycoprotein (sometimes also called spike protein, formerly known as E2) is the largest of the four major structural proteins found in coronaviruses. The spike protein assembles into trimers that form large structures, called spikes or peplomers, that project from the surface of the virion. The distinctive appearance of these spikes when visualized using negative stain transmission electron microscopy, "recalling the solar corona", gives the virus family its name. The function of the spike glycoprotein is to mediate viral entry into the host cell by first interacting with molecules on the exterior cell surface and then fusing the viral and cellular membranes. Spike glycoprotein is a class I fusion protein that contains two regions, known as S1 and S2, responsible for these two functions. The S1 region contains the receptor-binding domain that binds to receptors on the cell surface. Coronaviruses use a very diverse range of receptors; SARS-CoV (which causes SARS) an ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Recombinant Vaccine
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be |
List Of COVID-19 Vaccine Authorizations
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK. Seven others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Abdala, Zifivax, Corbevax, COVIran Barekat, and SCB-2019. Of the 40 vaccines, 16 have a full or emergency authorization in only one country, 12 in ten or fewer countries, and 12 in more than ten countries. Note that in some countries, vaccines may be authorized solely for travel purposes. They may not be approved for the general population. For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vaccination program; however, they are recognized for the p ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sinopharm BIBP COVID-19 Vaccine
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac. Peer-reviewed results published in ''JAMA'' of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 c ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> Clinical Trials")
